Logo

American Heart Association

  40
  0


Final ID:

Cardiac Myosin Inhibitors in HCM - Altering The Natural History or Am I Delusional?

  • Owens, Anjali  ( UNIVERSITY OF PENN , Walliford , Pennsylvania , United States )
  • Olivotto, Iacopo  ( Meyer Children’s Hospital IRCCS , Florence , Italy )
  • Author Disclosures:
    Anjali Owens: DO have relevant financial relationships ; Consultant:Alexion:Active (exists now) ; Consultant:Stealth:Active (exists now) ; Consultant:Corvista:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Imbria:Active (exists now) ; Consultant:Edgewise:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:Avidity:Active (exists now) ; Consultant:BMS:Active (exists now) ; Consultant:Biomarin:Active (exists now) ; Consultant:Bayer:Active (exists now) | Iacopo Olivotto: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy

Desai Milind, Paterson Natasha, Ivey Kathy, Tingley Whittemore, Nagueh Sherif, Giudicessi John, Pollman Matt, Varfaj Bardha, Harrison William, Lombardi Laura, Argast Gretchen, Tomlinson Latanya

Gene Therapy: The Next Frontier or Fool's Gold?

Seidman Christine, Watkins Hugh

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available